plasminogen like A (pseudogene)Genealiases: PLGLA1 · PLGP2 · PRGA
Q-omics provides the consensus-scored PLGLA profile across patient tissues and cancer cell-line models. PLGLA expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, PLGLA is differentially expressed in 6, with the highest sampling consensus in KIRP. Additionally, PLGLA RNA expression shows 6,376 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, KIRP, and STAD as cancer lineages where PLGLA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLGLA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLGLA survival associations across molecular data types. PLGLA RNA expression shows survival associations in the most cancer types (14), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLGLA RNA expression–survival associations across cancer types. High PLGLA expression shows unfavorable associations in STAD, TGCT and LUSC, but favorable associations in LIHC, BRCA and LUAD. The LIHC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for PLGLA RNA expression.
This table summarizes PLGLA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PLGLA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLGLA shows lower tumor expression in KIRP, KIRC, LIHC, CHOL and KICH and higher tumor expression in BRCA. The KIRP box plot shows higher PLGLA RNA expression in normal versus tumor tissue (log2 FC = −0.889, t-test p < 0.001).
This table shows molecular features associated with PLGLA in patient tissues and cancer cell lines. In patient samples, PLGLA shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
